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AAP = American Academy of Pediatrics; BPD = bronchopulmonary dysplasia; CLD = chronic lung disease; LRTI = lower respiratory tract infection;
RSV = respiratory syncytial virus; RSV-IGIV = respiratory syncytial virus immune globulin.
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Introduction
Respiratory syncytial virus (RSV) infection in previously
healthy children usually results in mild upper respiratory
tract disease that resolves spontaneously, but in a minority
(usually infants <3 months old) it causes serious disease. In
certain high-risk pediatric groups, however, severe lower
respiratory tract infection (LRTI) with considerable illness
and death is a more frequent occurrence. These groups
include preterm infants with and without chronic lung
disease (CLD), children with pulmonary or cardiac disease,
and immunocompromised children. Potential long-term con-
sequences of LRTI caused by RSV include possible associ-
ations with (and future development of) asthma, allergies,
and other chronic pulmonary illnesses. Some studies
suggest that severe RSV LRTI is associated with recurrent
wheezing, asthma, and other pulmonary sequelae [1–3].
Infection with RSV has far-reaching effects, with both the
US Centers for Disease Control and Prevention [4] and
the World Health Organization [5] reporting that RSV is
the leading cause of LRTI among infants and children
worldwide. Low income, poor nutrition, and low birth
weight are additional risk factors that are particularly
important in developing countries, where it has been esti-
mated that approximately four million children die each
year from acute respiratory tract infections [6]. An esti-
mated 100,000–125,000 hospitalizations and 100–450
deaths annually among infants and children in the USA are
attributed to RSV LRTI [7–9]. The number of children hos-
pitalized for bronchiolitis has also increased markedly in
the USA. From 1980 to 1996, hospitalization rates per
1000 children under 1 year old increased from 12.9 to
31.2 [7]. In most patients hospitalized for bronchiolitis
(50–90%) and in up to half of those for winter pneumonia
(20–50%), RSV is the underlying cause [10].
Reinfection is common in older children, adults, and the
elderly because, unlike a number of other infectious dis-
eases, infection with RSV does not confer protective and
enduring immunity. Therefore, individuals at high-risk (e.g.
those who are debilitated or geriatric patients, patients
with chronic heart or lung disease, or immunosuppressed
individuals) are also at risk for morbidity from the compli-
cations of RSV.
Respiratory syncytial virus (RSV) infects nearly all children by age 2 years, and it causes considerable
illness and death in certain high-risk pediatric populations. Historically, treatment for RSV has been
symptomatic, and developing a safe and effective vaccine has been a challenge. Therefore, research
efforts have turned to passive immunization as the best option to control RSV. Palivizumab, a
genetically engineered humanized monoclonal antibody, has been shown to reduce RSV-related
hospitalizations significantly, with few adverse effects. It was approved for use in high-risk children in
the USA in 1998 and in Europe in 1999; it is now approved for use in more than 45 countries. The
efficacy and safety of palivizumab continue to be supported by both clinical trial and outcomes data.
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Research for effective treatment strategies for RSV has
been ongoing for almost four decades with few suc-
cesses. Development of an effective RSV vaccine has
many challenges, including the need to induce immunity to
the multiple strains of RSV. Also, because the children at
highest risk are younger than 3 months, vaccination would
ideally take place when the child is still a newborn
(≤1 month old), raising concerns regarding possible inter-
ference by maternal antibodies to injectable vaccines. A
further concern is that because natural infection does not
prevent reinfection, a series of boosters may be needed.
Finally, the experience of enhanced pathology following
administration of a formalin-inactivated vaccine to naïve
infants in the 1960s upon subsequent RSV infection
[11,12] has tempered the development of injectable vac-
cines for RSV. Various animal models have been devel-
oped to study the enhanced pathology seen in these
infants, such as the cotton rat [13], mouse [14,15], and
monkey [16,17]. Live, attenuated RSV vaccines showed
promise in early trials because they did not result in more
severe disease after later natural infection with RSV, could
be given intranasally, and protected against RSV-induced
upper respiratory tract infections and LRTIs [18]. Like with
other live vaccines, however, vaccinees have the potential
to shed virus, and this live RSV vaccine has not been suffi-
ciently attenuated. A live, genetically engineered RSV
vaccine is a future prospect [19,20]. Subunit vaccines
that contain purified F and G glycoproteins or novel
chimeric substances splicing together F and G proteins
are currently being studied [21], as are DNA vaccines
[22]. However, current vaccination strategies are focused
on maternal immunization and live vaccines.
Passive immunoprophylaxis: immunoglobulins
During the 1980s passive immunoprophylaxis was studied
as an alternative to the live vaccines, which had failed to
provide acceptable protection against RSV infection. Early
studies in rats, as well as clinical observations in infants
infected with RSV, demonstrated that titers of RSV anti-
bodies needed to be between 1:200 and 1:400 to
prevent LRTI [23,24]. Standard immunoglobulin prepara-
tions did not adequately protect the lower respiratory tract
against RSV infection, seemingly because of the low titers
that could be achieved.
Introduction of respiratory syncytial virus immune
globulin
RSV immune globulin (RSV-IGIV; RespiGam™, MedIm-
mune Inc., Gaithersburg, MD, USA) contains a sixfold
higher concentration of RSV neutralizing antibodies than
do standard immunoglobulin preparations. It was devel-
oped to improve on the record of standard immunoglobu-
lin preparations, and specifically to provide passive
immunity against RSV in infants who were born preterm,
before the third trimester when maternal IgG antibodies
are typically passed from the mother to the fetus [25,26].
A 3-year, prospective, randomized, blinded, multicenter
study was conducted between 1989 and 1992 that com-
pared results after use of RSV-IGIV at doses of either 750
or 150 mg/kg with those in control individuals who did not
receive RSV-IGIV [23]. In the 249 infants and children born
prematurely, or with bronchopulmonary dysplasia (BPD) or
congenital heart disease (mean age 8 months), those
treated with the higher dose had a significantly lower rate
of LRTI, fewer and shorter hospitalizations, fewer admis-
sions to the intensive care unit, and required less of the
antiviral agent ribavirin than did control individuals. During
the 1994–1995 RSV season, these results were replicated
in a larger multicenter study in the US-based PREVENT
study of 510 infants and children born prematurely or with
BPD [24]. In that randomized, double-blind, placebo-con-
trolled study, hospitalization was reduced by 41% and
RSV-IGIV was found to be safe and well tolerated.
Limitations of respiratory syncytial virus immune globulin
Although RSV-IGIV offered distinct advantages over the
formalin-inactivated vaccine (primarily protection of the
lower respiratory tract without more severe infection after
later challenge with wild-type virus), it also has various lim-
itations. For example, it is not effective in children with
congenital heart disease or cyanotic heart disease
because of hyperviscosity, and was responsible for more
hypercyanotic events than was albumin [27]. In addition,
administration of RSV-IGIV is time-consuming and incon-
venient, involving 3- to 4-hour intravenous infusions of
large fluid volumes and protein loads each month. This
can lead to fluid overload in some children [23,24] and is
of special concern when children, particularly infants, have
chronic cardiopulmonary conditions.
Monoclonal antibodies
Monoclonal antibodies were investigated in an effort to
avoid the difficulties associated with RSV-IGIV. The first
monoclonal preparations could be administered
intranasally, thereby protecting the portal of entry and pre-
cluding the difficulties associated with parenteral therapy.
In a study using rhesus monkeys [28], a mouse mono-
clonal IgA antibody against RSV F glycoprotein was
administered as nose drops. The monkeys developed high
titers of RSV neutralizing antibodies, but this finding was
not repeated in human phase III clinical trials and efficacy
could not be proved. In addition, because the half-life of
IgA is short, dosing schedules would require repeated
applications, hence reducing the likelihood of compliance.
Likewise, a clinical trial with the intramuscular IgG human-
ized monoclonal antibody SB 209763 also failed to
produce favorable results [29,30]. The development of a
humanized monoclonal antibody produced by recombinant
DNA technology – palivizumab – represented a major
advance in protection against RSV.S28
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Experience with palivizumab
Palivizumab (Synagis®; MedImmune Inc., Gaithersburg,
MD, USA) is a humanized monoclonal antibody (IgG1) that
is directed at an epitope on the A domain of the F glyco-
protein on the surface of the RSV. Its mechanism of action
is to neutralize and inhibit the fusion activity of both types
A and B clinical RSV isolates on respiratory epithelial cells
[31]. Unlike RSV-IGIV, palivizumab is not derived from
human blood and does not require intravenous administra-
tion. Its greater safety and convenience of use are clear
advantages over previous methods of passive immunopro-
phylaxis. It is administered seasonally to high-risk individu-
als by monthly intramuscular injections.
The IMpact-RSV study
The IMpact-RSV study was the basis for approval of
palivizumab by the US Food and Drug Administration and
by the European Agency for the Evaluation of Medicinal
Products. That randomized, double-blind, placebo-con-
trolled study (conducted between 1996 and 1997)
demonstrated that palivizumab could safely and effectively
be administered to children who are at high risk for serious
LRTI associated with RSV. Patients involved in the study
were from 139 centers across the USA, the UK, and
Canada. Each of 1502 children born prematurely and/or
with BPD received either five monthly injections of
palivizumab intramuscularly (15 mg/kg) or treatment with
an equivalent dose of placebo. The children were moni-
tored for hospitalization rates, LRTI, duration of hospital
stay, and use of supplemental oxygen and/or mechanical
ventilation or other intensive care procedures [32].
Adverse events were infrequent, and 99% of children in
both the palivizumab and placebo groups completed the
treatment protocol [32]. Overall hospitalization rates for
RSV infection were reduced by 55% in children who
received palivizumab (4.8%) as compared with rates in
children who received placebo (10.6%; P<0.001). Hospi-
talization rates were reduced by 78% in children without
BPD and by 39% in children with BPD. Among the latter
group of children, hospitalization rates were 7.9% for
those who received palivizumab versus 12.8% for those
who received placebo. Finally, hospitalization rates for
preterm infants were 1.8% in those who received
palivizumab versus 8.1% in those who received placebo.
In addition to being the pivotal study for safety and effi-
cacy of palivizumab, the IMpact-RSV study served as the
basis for the usage guidelines of the American Academy
of Pediatrics (AAP) [33] and the European consensus
guidelines [34]. The AAP recommended the following cri-
teria be used to determine eligibility for prophylaxis with
palivizumab [33]: infants born at ≤28 weeks of gestation
and who are under 1 year old at the start of the RSV
season; infants born at 29–32 weeks of gestation and
who are under 6 months old at the start of RSV season;
infants born at 32–35 weeks of gestation, who are under
6 months old at the start of RSV season, and are at higher
than average risk for RSV exposure (e.g. through day-care
attendance or school-age siblings); and children under
2 years old who have a CLD requiring medical manage-
ment in the last 6 months.
Initial field experience
During the first RSV season (1998–1999) after approval
in the USA, palivizumab was administered to approxi-
mately 56,000 patients. Results of the initial field experi-
ence analyzed through a retrospective review of the charts
of 1839 patients from nine sites in the USA [35] were
consistent with those obtained in the IMpact-RSV study.
The hospitalization rate for RSV infection in patients who
received palivizumab was 2.3%, with only 42 out of the
1839 patients requiring hospital admission. Hospitaliza-
tion rates were 4.0% (16 out of 399) for patients with
CLD, and 2.1% (26 out of 1227) for premature infants
without CLD.
During the second season of palivizumab use
(1999–2000) field experience was again evaluated by
means of a retrospective chart review, this time in 2830
children from 12 sites in the USA [36]. Again, results were
consistent with those of the IMpact-RSV study. The hospi-
talization rate for RSV-related illness was 2.4% (68 out of
2830) in children who received palivizumab. Rates were
3.9% (31 out of 795) in children with CLD and 1.3% (34
out of 2542) in otherwise healthy but preterm infants [36].
During the third season (2000–2001), experience with
palivizumab was evaluated via use of the Synagis Out-
comes Registry [37]. This prospective, multicenter effort
involved 2095 children given palivizumab according to the
monthly dosing protocol at 62 pediatric offices and clinics
across the USA. The data collected added to the favor-
able profile of palivizumab administration that had already
been observed in the IMpact-RSV study and the previous
retrospective investigations. The infants involved in the
Synagis Outcomes Registry were mostly Caucasian, with
947 considered high-risk because their gestational age
was between 32 and 35 weeks and, in 66% of the group,
because of one or more additional risk factors. These risk
factors included multiple birth (32%), CLD (24%), child
care by either the child or a sibling (22%), exposure to
tobacco smoke (16%), congenital heart disease (5%), and
cystic fibrosis (0.6%). In that investigation, hospitalization
rates were 2.9% overall, 5.8% in infants with CLD, and
2.1% in premature infants without CLD.
Global experience
A phase III/IV multicenter, single-arm, open-label,
expanded access study was performed between Novem-
ber 1998 and March 1999 in 15 countries in the northern
hemisphere because palivizumab was not approved forS29
use in all countries [38]. Children were included in the
study based on the AAP guidelines discussed above.
Palivizumab was administered intramuscularly to each
child at a dosage of 15 mg/kg, according to the monthly
dosing protocol. The children were monitored for adverse
events for 150 days, during which time 40 drug-related
adverse events were reported in 39 children (6.9%). All of
the reported adverse events were mild or moderate, with
injection site reactions being most common (12 out of
530). Fever was reported in eight children, and diarrhea
and irritability in four. Two children died, but the deaths
were unrelated to either RSV or receiving palivizumab. In
approximately 25% of the children tested for RSV (7 out
of 29), RSV was the cause of hospitalization. Considering
this rate to be a reasonable assessment of RSV infection
among children who were not actually tested, the esti-
mated overall hospitalization rate was 2.1%. The low inci-
dence of adverse events and low hospitalization rates
reported support earlier studies of the safety, tolerability,
and effectiveness of palivizumab.
In France palivizumab was made available to high-risk chil-
dren before approval by the European Agency for the Eval-
uation of Medicinal Products by permission of the French
Agency for the Safety of Health Products. Because this
was an observational field survey, there was no control
group, blinding, or randomization (unpublished data). Data
were collected on 516 preterm infants (median gestational
age 28 weeks, with 88% born at or before 32 weeks) who
received one to five monthly injections of palivizumab. The
rate of BPD was 81%, which is higher than in the IMpact-
RSV and PREVENT studies. The hospitalization rate for
RSV disease was 7.6% (n = 39), with 10 infants requiring
intensive care and four requiring mechanical ventilation.
There were no deaths attributed to administration of
palivizumab.
In Canada, a special access program was instituted to
allow use of palivizumab in high-risk children before its
approval by Canadian regulatory authorities. Use of
palivizumab and compliance with dosing schedules were
monitored in the COMPOSS study (Compliance, Out-
comes, Management: a Prospective, Observational Study
of Synagis in Canada) [39], which was conducted during
the 1999–2000 season. Among the 480 infants who were
born prematurely and/or had BPD, compliance was high;
77% of the 1700 doses given were administered accord-
ing to the recommended schedule, and only two infants
were withdrawn from the program because of perceived
adverse effects. Hospitalization rates for RSV were even
lower than those in other studies, at 2.4% overall (1.6% in
premature babies and 6.0% in infants with BPD). This
overall rate was half that seen in the IMpact-RSV study
(4.8%), possibly because the latter study included more
children with BPD. COMPOSS did not have a control
group, and therefore direct comparison with the IMpact-
RSV study is not possible. Nevertheless, hospitalization
rates due to RSV in the placebo groups of both the
PREVENT and IMpact-RSV studies were substantially
higher than those in COMPOSS.
In The Netherlands, a retrospective analysis was con-
ducted in 450 children who received palivizumab during
the 1999–2000 season [40]. The children involved were
either born preterm, or had chronic pulmonary and/or
cardiac disease, and/or immunodeficiency. Evaluation
forms were completed by the children’s pediatricians
(70% response rate), and data were collected on sex,
date of birth, gestational age, risk factors for serious RSV
infection, and hospitalization rates. Of the children who
received palivizumab, only 1.6% overall (4 out of 254)
were hospitalized for RSV infections; in infants born at
29–32 weeks of gestation, hospitalization rates were
0.8% in those without CLD and 6.7% in those with CLD.
Additional data on the safety and tolerability of palivizumab
were collected in the PROTECT (Palivizumab RSV Open-
label Trial of Effectiveness and Clinical Tolerability) study
[41]. In that study, which was conducted in 35 centers in
17 countries, the preterm infants (born at gestational age
between 29 and 32 weeks) included differed from those
in other studies in that they did not have pulmonary
disease. In children 6 months old or younger (n = 285)
who received palivizumab monthly at a dosage of
15 mg/kg intramuscularly, the most commonly reported
adverse events were cough, rhinitis, pharyngitis, bronchi-
olitis, fever, and diarrhea. Twenty children were hospital-
ized for respiratory infections; six tested positive for RSV
and 14 tested negative. The rate of hospitalization due to
RSV was 2.1%.
Continued experience in Europe
Because palivizumab is partly murine derived, there is a
theoretical, although unlikely, possibility that a person
could mount an immune response (e.g. antibody forma-
tion, or allergic or anaphylactic responses) to these com-
ponents on repeated exposure. A study conducted to
investigate potential immunologic events, as well as to
continue to collect data on safety and efficacy, was con-
ducted in 14 centers in Europe and Canada [42]. A total
of 134 children were included; palivizumab was adminis-
tered to 71 of the children for the first time and to 63 of
the children for their second season. No immune reac-
tions, including production of antipalivizumab antibodies,
or other serious adverse events were observed. Mean
serum trough levels of palivizumab were greater than
30–40 µg/ml in all children, which is adequate for protec-
tion against RSV. The hospitalization rate due to RSV
infection was 4.2% overall.
Because of the previous problems of increased disease
severity after challenge with wild-type virus associated with
Available online http://respiratory-research.com/content/3/S1/S26S30
the formalin-inactivated vaccine, a phase III/IV cohort
follow-up study was conducted [43]. In that study, data
collected from children in Europe and Canada showed no
difference between treated and control groups in overall
hospitalization rates or occurrence of adverse events. The
treated group consisted of children who had received at
least two doses of palivizumab during the previous RSV
season; the control group consisted of children who had
never received palivizumab. The two groups were matched
in terms of sex and gestational age. The study showed that,
unlike the old formalin-inactivated vaccine, palivizumab
does not cause more frequent or severe RSV disease.
Combined analysis of hospitalization rate data
A meta-analysis of RSV hospitalization in various risk
groups is summarized in Table 1 and Fig. 1. Hospitaliza-
tion rates were examined in both prophylaxed and unpro-
phylaxed children in a combined analysis of the data from
numerous studies [44]. The studies included were either
prospective or retrospective, and either controlled trials or
not. However, in all studies the following had to apply:
hospitalization rates had to have been defined as the total
number of patients hospitalized due to RSV at least once
divided by the total number of patients in the study; and
subpopulations had to have been clearly defined. The
three subpopulations examined were children younger
than 2 years old with BPD/CLD, infants at gestational age
29–32 weeks without CLD, and infants at gestational age
32–35 weeks without CLD. In each subpopulation, hospi-
talization rates were considerably lower in patients who
had been treated with palivizumab than in those who had
not. In the BPD/CLD children, rates were 17.9% and
5.6% for those who received palivizumab and did not
receive palivizumab, respectively. In the infants at gesta-
tional age 29–32 weeks the corresponding rates were
10.2% and 2.0%, and in the infants at gestational age
32–35 weeks the rates were 9.8% and 1.5%.
Special uses
Many children who do not meet the official AAP criteria for
eligibility to receive palivizumab [33] may still benefit from
and may be considered for treatment. In one study [45]
palivizumab was administered to 86 children who did not
meet the AAP criteria but had BPD when they were aged
2 years or older, or had other chronic illnesses including
cerebral palsy, trisomy 21, chronic aspiration, severe tra-
cheomalacia, cystic fibrosis, or myotonic dystrophy. No
adverse events or deaths were reported, and the hospital-
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Table 1
Hospitalization rates
Children ≤2 years old  Infants at gestational age Infants at gestational age
with BPD/CLD  29–32 weeks without CLD  32–35 weeks without CLD 
(n = 3675) (n = 4854) (n = 2829)
Reference (country) Untreated Palivizumab Untreated Palivizumab Untreated Palivizumab
[23] (USA) 36.7% (30) – – – – –
[24] (USA) 17.4% (149) – – – – –
[52] (USA) 25.2% (131) – 7.6% (662) – – –
[53] (UK) 19.1% (235) – – – – –
[32] (USA/Can/UK) 12.8% (266) 7.9% (496) 8.5% (142) 1.6% (313) 9.8% (123) 2.0% (250)
[35] (USA; outcomes 1998–1999) – 4.0% (402) – 2.0% (506) – 1.5% (548)
[36] (USA; outcomes 1999–2000) – 3.9% (795) – 2.3% (690) – 1.3% (972)
[39] (Canada) – 6.0% (95) – 1.3% (199) – –
[40] (The Netherlands) – 3.4% (88) – 0.8% (124) – –
Unpublished data (France) – 7.6% (506) – – – –
[37] (USA; registry 2000–2001) – 5.8% (482) – 2.3% (650) – 1.6% (936)
[54] (Spain) – – 10.1% (456) – – –
[55] (Spain) – – 12.9% (827) – – –
[41] (international study) – – – 2.1% (285) – –
Weighted mean rate 18.4% (811) 5.6% (2864) 10.3% (2087) 2.0% (2767) 9.8% (123) 1.5% (2706)
Values are expressed as % (n). Hospitalization rates due to respiratory syncytial virus (RSV) in children ≤2 years old with bronchopulmonary
dysplasia (BPD)/chronic lung disease (CLD), infants at gestational age 29–32 weeks without CLD, and infants at gestational age 32–35 weeks
without CLD (combined analysis). –, not studied. Adapted from Simoes [44].S31
ization rate was 3.5%, although the rate in populations
without prophylaxis is unknown.
Palivizumab has been used as prophylaxis during nosoco-
mial outbreaks. Because RSV is ubiquitous in the environ-
ment, can be shed for up to 4 weeks in newborns, and can
remain on fomites for up to 7 hours and on skin for 30 min
[46], it causes nosocomial outbreaks in nurseries and inten-
sive care units. Until the introduction of palivizumab, the only
mechanisms to control RSV nosocomial outbreaks were
standard infection control techniques, including handwash-
ing, minimizing contact between hospital personnel and
infected patients, using gowns and gloves, and disinfecting
processes. Although use of palivizumab in such situations is
off-label, it has been used in several hospitals in Europe to
protect infants against nosocomial RSV infection.
Such nosocomial outbreaks have occurred and been con-
trolled with use of palivizumab in the UK, Spain, and Portu-
gal. In Northamptonshire, UK (November–December
1999), seven preterm infants in a special care unit devel-
oped RSV infections [47]. One of the infants developed
severe bronchiolitis and pneumonia that resulted in death.
Eight other high-risk infants who were administered
palivizumab at 15 mg/kg did not develop RSV infection.
In Barcelona, Spain (1999), similar results were observed
in a larger study involving 52 neonates during an outbreak
of RSV with four confirmed cases [48]. All of the infants
received palivizumab. Three out of the four infants who
had confirmed RSV infections were tested and were
found to be free of RSV 6 days after administration of
palivizumab. None of the other 48 neonates developed
RSV infection, with no adverse events. No deaths were
reported and mechanical ventilation was not needed. A
similar outbreak that had occurred in that same care facil-
ity 11 years previously – using the same infection control
techniques but before palivizumab was available –
resulted in an RSV infection rate of 32% and an inability to
accept new admissions into the facility for 7 weeks.
In Portugal (November–December 1998), two outbreaks
of RSV occurred 2–3 months apart in a neonatal unit
caring for 19 infants (data on file, Abbott Laboratories).
Despite implementation of standard infection control tech-
niques after three neonates developed RSV infection,
infection developed in eight more of the neonates. One of
the infants died and three others needed respiratory
support via mechanical ventilation. After all neonates
received palivizumab, no further RSV infections developed
and the outbreak was stopped.
Although none of those studies was controlled, the results
suggest that administration of palivizumab may be useful
in preventing nosocomial spread of RSV. Additional
research is warranted for confirmation.
Continued field monitoring of palivizumab
A favorable safety profile has been documented over the
four seasons of use of palivizumab. Pharmacovigilance
measures are in place to continue to confirm the safety
profile. Such measures increase the possibility of identify-
ing any serious or infrequent adverse events through
reporting of such events in larger and more varied patient
groups under conditions of field use.
Between October 1998 and June 2001, a total of
272,879 patient exposures occurred (data on file, Abbott
Laboratories). When the incidence of adverse events was
compared with that in the IMpact-RSV trial, no increase
was seen. Urticaria was seldom reported (20 out of
125,546 exposures [0.016%]). The overall frequency of
death was not greater in patients who received
palivizumab, and none of the 121 deaths reported were
related to administration of palivizumab.
More than five monthly palivizumab injections may be
required in countries with an extended RSV season.
Safety was assessed in this situation by examining the
records of 433 infants who had received six or more treat-
ments with palivizumab [49]. In those infants the rate of
hospitalization due to RSV was 2.1% and the rate of
adverse events was 1.6%. These findings compare favor-
ably with those of the IMpact-RSV study, in which no more
than five treatments were given.
Conclusion
Palivizumab is a humanized monoclonal antibody that is
administered via monthly injections and confers passive
immunity against development of severe RSV disease in
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Figure 1
Weighted mean hospitalization rates due to respiratory syncytial virus
(RSV; standard deviation indicated by vertical bars) in children
≤2 years old with bronchopulmonary dysplasia (BPD)/chronic lung
disease (CLD), in infants at 29-32 weeks’ gestational age (wGA)
without CLD, and in infants at 32–35 wGA without CLD (combined
analysis). Data from Simoes [44].S32
high-risk children. Multiple studies and postmarketing
experience involving thousands of preterm and high-risk
infants in various demographic groups have demonstrated
that treatment with palivizumab decreases overall rates of
hospitalization due to RSV. Palivizumab enjoys an excel-
lent overall safety profile, as confirmed by the low inci-
dence of adverse events in multiple studies and in phase
IV testing conducted since its first season of use.
Thus far, the search for a safe and effective vaccine
against RSV has not succeeded, and clinical outcomes in
studies of children treated symptomatically for RSV with
bronchodilators, steroids, and antiviral agents (ribivarin)
have not been improved [50,51]. Until such a vaccine is
discovered and proven, palivizumab remains the only safe,
effective, and convenient treatment to prevent RSV
disease in young children who are at risk.
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